SAB Biotherapeutics (SABS) Research & Development (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Research & Development data on file, last reported at $13.4 million in Q1 2026.

• Quarterly Research & Development rose 74.97% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 million (up 33.81% YoY) and the FY2025 annual result came in at $34.4 million, up 13.56% from the prior year.
• Research & Development climbed to $13.4 million in Q1 2026, from $10.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $13.4 million in Q1 2026 to a low of $3.7 million in Q2 2023.
• A 5-year average of $7.7 million and a median of $7.7 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development plunged 65.96% — and 2024, when it jumped 94.81%.
• Tracing SABS's Research & Development over 5 years: stood at $7.1 million in 2022, then tumbled by 39.8% to $4.3 million in 2023, then jumped by 78.05% to $7.7 million in 2024, then surged by 40.21% to $10.7 million in 2025, then rose by 24.88% to $13.4 million in 2026.
• The last three Research & Development figures came in at $13.4 million (Q1 2026), $10.7 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.